Advancements in targeted therapies are shaping the neuroblastoma market

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Large Will The Neuroblastoma Market Be By 2030 Compared To Its 2026 Market Size?

The neuroblastoma market has seen significant expansion in recent years. Its valuation is anticipated to increase from $3.14 billion in 2025 to $3.32 billion in 2026, growing at a compound annual growth rate (CAGR) of 5.8%. The observed growth over previous periods can be linked to a higher occurrence of pediatric neuroblastoma, the prompt adoption of chemotherapy protocols, the creation of immunotherapy vaccines, improvements in clinical diagnostic capacities, and increased public understanding of childhood cancer symptoms.

The neuroblastoma market is projected to experience substantial expansion over the upcoming years, reaching $4.12 billion by 2030, driven by a compound annual growth rate (CAGR) of 5.5%. This anticipated growth during the forecast period can be linked to several factors, including the broadening of targeted therapy investigations, heightened investment in cell therapy offerings, increased uptake of precision oncology techniques, the creation of novel pediatric immunotherapy treatments, and advancements in diagnostic imaging for earlier detection. Key developments during this timeframe are expected to encompass a greater acceptance of immunotherapy vaccines for pediatric cancer, expanded utilization of targeted oral chemotherapy drugs, the escalating progress of monoclonal antibody therapies, the broadening scope of cell therapy and regenerative oncology strategies, and an intensified emphasis on prompt diagnosis and effective symptom management.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20901&type=smp

Which Drivers Are Supporting The Neuroblastoma Market Growth?

The neuroblastoma market is anticipated to expand due to a rising occurrence of childhood cancer. Childhood cancer encompasses various malignancies predominantly affecting young individuals, often impacting vital organs like the brain, blood, and bones, thus requiring specific therapeutic strategies. This increase in childhood cancer cases can be linked to enhanced diagnostic methods, greater public awareness, environmental factors, genetic susceptibilities, and progress in medical research. Neuroblastoma treatments offer focused interventions for pediatric cancers, facilitating prompt and effective care that reduces recurrence risks and enhances prospects for young patients. For example, according to the American Cancer Society, a US-based professional organization, in May 2024, projections for 2024 estimated around 9,620 children under 15 in the United States would be diagnosed with cancer, a significant rise from 5,290 cases reported in 2023. Consequently, the growing incidence of childhood cancer is a key factor propelling the expansion of the neuroblastoma market.

What Are The Different Segment Types In The Neuroblastoma Market Segment Breakdown?

The neuroblastoma market covered in this report is segmented –

1) By Product Type: Tablets, Vaccines, Other Product Types

2) By Treatment Type: Chemotherapy, Immunotherapy, Other Treatment Types

3) By Distribution Channel: Online, Offline

4) By End-User: Hospitals, Clinics

Subsegments:

1) By Tablets: Oral Chemotherapy Tablets, Targeted Therapy Tablets

2) By Vaccines: Immunotherapy Vaccines, Therapeutic Vaccines

3) By Other Product Types: Injectable Drugs, Monoclonal Antibodies, Cell Therapy Products

Which Trends Are Expected To Impact The Neuroblastoma Market?

Leading companies in the neuroblastoma market are concentrating on developing advanced therapeutic interventions, such as humanized anti-GD2 monoclonal antibodies, to target and treat cancer cells more effectively and safely. A humanized anti-GD2 monoclonal antibody is specifically engineered to target the GD2 molecule on cancer cells while reducing immune rejection by incorporating human components. For instance, in August 2023, Renaissance Pharma Ltd., a UK-based clinical-stage pharmaceutical company, announced that it had in-licensed Hu14.18K322A (Hu14.18) from St. Jude Children’s Research Hospital. This particular antibody is intended for the treatment of newly diagnosed high-risk neuroblastoma, which is a rare and aggressive childhood cancer. According to the terms of the agreement, Renaissance has obtained exclusive rights to develop, manufacture, and commercialize Hu14.18 across major global markets, including the United States, Canada, Europe, China, Japan, and Turkey.

Who Are The Well-Known Companies In The Neuroblastoma Market?

Major companies operating in the neuroblastoma market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Sartorius AG, Recordati S.p.A, United Therapeutics Corporation, BeiGene Ltd., MacroGenics Inc., Y-mAbs Therapeutics Inc., RedHill Biopharma Ltd., Clarity Pharmaceuticals Ltd., EUSA Pharma (UK) Ltd., US WorldMeds LLC, Ascentage Pharma, Laboratorio Elea Phoenix S.A, Curis Inc., PersonGen BioTherapeutics (Suzhou) Co. Ltd., Essential Pharma S.A, Cellectar Biosciences Inc., Provectus Biopharmaceuticals Inc.

Get The Full Neuroblastoma Market Report:

https://www.thebusinessresearchcompany.com/report/neuroblastoma-global-market-report

Which Region Is The Largest In The Neuroblastoma Market?

North America was the largest region in the neuroblastoma market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neuroblastoma market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Neuroblastoma Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/neuroblastoma-global-market-report

Browse Through More Reports Similar to the Global Neuroblastoma Market 2026, By The Business Research Company

Fibromyalgia Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/fibromyalgia-treatment-global-market-report

Muscle Pain Treatment Market Report

https://www.thebusinessresearchcompany.com/report/muscle-pain-treatment-global-market-report

Migraine Treatment Market Report

https://www.thebusinessresearchcompany.com/report/migraine-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795